Mr. Dey co-founded Bluejay Diagnostics in 2015. He co-founded LMBRI, LLC in 2007. LMBRI, which became inactive in 2017 was a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and EU.
During his tenure with LMBRI, he spent about 8 years consulting with Toray Industries, Hitachi Chemicals (now Showa denko Materials Co. Ltd.)., Fuji Chemicals, among others.
Prior to that he held a number of executive roles. From 2005-2007 he was Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca). From 2001-2005 he was Head of Business Development, Western U.S. for IMPATH, Inc. where he was responsible for three business units and the introduction of new product Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc., Manager, Technology Licensing, Thomas Jefferson Medical University, Manager, Technology Licensing, Ciba Geigy (Novartis).
Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva-Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Masters in Business Administration (Fulbright Scholarship) from the University of Cambridge.
Ms. Dey co-founded Bluejay Diagnostics in 2015. She also co-founded LMBRI, LLC in 2007, a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and India. LMBRI, LLC became inactive in 2017.
She was the President & CEO of LMBRI, LLC and is a Board Member of Laminar Pharma, Inc. Prior to LMBRI she spent more than 15 years in healthcare consulting businesses.
In these roles, she has been involved in management and operations of healthcare and life sciences products development, sales & marketing operation and general management for more than 12 years. Earlier in her career, Ms. Dey served in different management roles in retail business across Russia and Europe. She earned a Masters Degree in Mathematics from the State University of Mari El Republic, Russia.
Dr. Cook joined the Company in 2021. From 2014 to 2021, Dr. Cook served as the chief executive officer of NanoHybrids, Inc., a nanotechnology company specialized in the development and manufacture of theranostic nanoparticle platform technologies.
He was also a director and served as chairman of its board from 2020-2021, and from 2014 to 2017, he served as senior scientist developing many of the core technologies of the company.
Dr. Cook earned a Ph.D. in Biomedical Engineering from University of Texas at Austin focusing on medical diagnostic system design and development. His postdoctoral work focused on the improvement of bioconjugation strategies of nanoparticles for molecular targeting. Dr. Cook also serves as an ad-hoc reviewer for numerous panels at the National Institute of Health and peer reviewed scientific journals.
Mr. Vance joined the Company in 2021. Prior to that, Mr. Vance served as Chief Business Development Executive for Vibra Healthcare from 2016 – 2018, an operator of 46 long term acute care hospitals.
From 2013-2016, Mr. Vance was Director of Business Development for the Commercial Division at Lifebridge Health Systems, which was converting multiple hospital and entities into an Accountable Care Organization (ACO) system.
He was responsible for joint ventures and the expansion of commercial services, including Urgent Care, Outpatient Surgery, Out Patient Physical Therapy, Sleep Centers, Homecare, Retail Pharmacy among others.
Prior to Lifebridge Health he was Senior Executive Director of Business Development and Marketing for UMass Memorial Healthcare, a seven hospital system, from 2005- 2011. He earned a Masters of Business Administration degree in Finance from Western New England College and a Bachelor of Science degree in Industrial Engineering and Operations Research from the University of Massachusetts.
Mr. Kinder joined the Company in 2021 with over 15 years of experience in finance and accounting at early-to mid-stage high technology companies. Prior to joining Blue Jay, he held senior management positions at startups as well as established companies.
Most recently, he was Managing Director with Capella Financial Services, a CFO consultancy focusing on high-tech, software and biotech clients.
Prior to Capella he led the finance, operations, accounting, HR, IT, legal, and due diligence team at Blue Sky Biotech, including the sale of the company to LakePharma. Mr. Kinder subsequently spent a year with LakePharma overseeing the integration. He began his career at Ernst & Young. Mr. Kinder holds a Master of Business Administration and Master of Science in Accounting from Northeastern University and a BA in History from Kenyon College. He is also a Certified Public Accountant and a Chartered Financial Analyst.